This article is more than 5 years old. Information may no longer be current.

Akorn signs supply agreement for thimerosal-free hyaluronidase

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BUFFALO GROVE, Ill. — Akorn has signed an exclusive agreement with PrimaPharm for a preservative-free, thimerosal-free formulation of hyaluronidase, Akorn announced in a press release. PrimaPharm will supply the drug, and Akorn will have exclusive marketing rights in the United States and Puerto Rico. Akorn expects to launch the drug in the first half of this year.

Hyaluronidase is used to improve the absorption and dispersion of injected drugs. The principal advantage of Hydase 150 units/mL (hyaluronidase injection) over other formulations of hyaluronidase is that Hydase does not contain thimerosal, a mercury-containing agent, an Akorn official said in the release.